Clinical Trials
50
Active:5
Completed:8
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:4
Phase 2:16
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (40 trials with phase data)• Click on a phase to view related trials
Phase 2
16 (40.0%)Not Applicable
9 (22.5%)Phase 3
9 (22.5%)Phase 1
4 (10.0%)Early Phase 1
1 (2.5%)Phase 4
1 (2.5%)Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Phase 2
Recruiting
- Conditions
- Biphenotypic Acute LeukemiaAcute Lymphoblastic LeukemiaMyeloblastic LeukemiaBilinear LeukemiaMalignant Lymphoma, Non-HodgkinMyelodysplastic Syndrome
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Target Recruit Count
- 50
- Registration Number
- NCT06756152
- Locations
- 🇷🇺
National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, Russian Federation
Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis
Active, not recruiting
- Conditions
- Primary Hemophagocytic Lymphohistiocytosis
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 7
- Registration Number
- NCT06587191
- Locations
- 🇷🇺
Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Phase 2
Active, not recruiting
- Conditions
- Acute Myeloid LeukemiaBiphenotypic Acute LeukemiaMyelodysplastic SyndromesAcute Lymphoblastic LeukemiaMalignant Lymphoma
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-08-23
- Target Recruit Count
- 150
- Registration Number
- NCT06475820
- Locations
- 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Samory-Mashela,1, Russian Federation
Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification
Recruiting
- Conditions
- GanglioneuromaNeuroblastomaGanglioneuroblastoma
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-05-20
- Target Recruit Count
- 200
- Registration Number
- NCT06296732
- Locations
- 🇷🇺
Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
Phase 2
Recruiting
- Conditions
- Inborn Errors of Immunity
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Target Recruit Count
- 100
- Registration Number
- NCT06199427
- Locations
- 🇷🇺
HSCT department, Moscow, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found